| INTRODUC TI ON
Tumor mutational burden, an emerging characteristic in cancer, was first highlighted by next-generation sequencing analysis. 1 A TMB increase in the human cancer genome has been attributed to both endogenous factors and environmental damage. 2 A number of clinical trials have revealed that TMB is correlated with the rate of response to programmed cell death-1 and programmed cell death ligand-1
(also known as PDCD1/PD-1 and CD274/PD-L1, respectively) immune checkpoint blockade. 3 The measurement of TMB is valuable not only to surmise cancer characteristics but also to predict the clinical response to immunotherapy.
Although TMB only represents the accumulation of somatic mutations, mutational signatures consisting of 96 nucleotide substitution patterns specifically reflect multiple cancer processes. 1, 4 Pan-cancer large-scale analyses have revealed particular mutational signatures attributed to several endo/exogenous factors, and 30 signature patterns are currently registered in the COSMIC database (https://cancer.sanger.ac.uk/cosmic/). 5 Defective DNA replication/ repair or exogenous stimuli, including UV radiation, tobacco smoking, alcohol, and chemicals, cause biased accumulation of somatic mutations, which result in corresponding signatures in specific tumors. 1, 6, 7 Mutational signatures thus represent informative tumor characteristics together with TMB variation. Although mutational signatures are considered to be predictors of tumorigenesis with equal importance to TMB, the mechanism leading to mutation accumulation in signatures remains unclear.
To predict and guide the response to immunotherapies, an indepth understanding of the complexity and dynamics of the immune context in the tumor microenvironment is necessary. 8 A component of the tumor microenvironment, ie, intratumoral immune cells, can be explored by analyzing the expression of multiple immune-related genes. 9 Recently, bioinformatics analysis using The Cancer Genome Atlas dataset revealed that the tumor microenvironment is influenced by the TMB. 10, 11 However, the relationship between mutational signatures and the immune context of the tumor microenvironment is less understood.
In the current study, to investigate the characteristics of TMB and mutational signatures, we carried out WES in over 4000
Japanese patients with cancer, revealing that mutation frequency and signature patterns were similar to those reported by previous studies focusing on Caucasian patients. Eight main mutational signatures, ie, MSI, smoking, POLE, APOBEC, UV, MMR, DSBR, and Signature 16, were found. Although Signature 16 is known to be associated with hepatocellular carcinoma in drinkers, it showed a higher contribution ratio in hypopharynx cancer. Tumors with a predominant MSI signature are potential candidates for treatment with immune checkpoint inhibitors such as pembrolizumab and were found in 2.8% of Japanese patients. According to the evaluation of the tumor microenvironment using multiple immune-related genes, tumors with predominant signatures were classified into 2 subgroups. The identified subpopulations also differed in intratumor genetic heterogeneity, possibly associated with distinct responses to immunotherapeutics. Tumor mutation burden and mutational signature analysis including the tumor microenvironment not only identify mutation-driven tumors but could also help immunotherapy.
| MATERIAL S AND ME THODS

| Patients and specimens
Informed consent was obtained from all patients and the Institutional Review Board of the Shizuoka Cancer Center (Nagaizumi, Japan) approved all aspects of this study (authorization no. [25] [26] [27] [28] [29] [30] [31] [32] [33] . All experiments using clinical samples were carried out in accordance with the approved guidelines. Tumors and surrounding normal tissue (≥0.1 g)
were dissected from surgical specimens immediately after resection of the lesion. The tumor samples were visually assessed by a clinical pathologist in our hospital when tumor content was 50% or more. In addition, peripheral blood was collected as a control for WES.
| DNA and RNA isolation
For DNA analysis, tumor and normal tissues were immediately frozen in liquid nitrogen prior to DNA extraction. DNA was extracted from tissues and peripheral blood samples using a QIAamp DNA and then shaken with a 5-mm zirconia bead using a TissueLyser II (Qiagen) for 10 minutes at room temperature. The extracted RNA sample was quantified using a NanoDrop spectrophotometer and its quality checked using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Samples with a RIN 12 less than 6.0 were discarded.
| Next-generation sequencing
The exome library for WES was constructed using an Ion Torrent 
| Sequencing workflow for identification of somatic mutations
The binary raw data derived from the semiconductor DNA sequencer were converted using Torrent Suite software (version 4.4, Thermo
Fisher Scientific) into BAM files that were mapped to the reference human genome (UCSC hg19 and FACETS. 26 Mutational signature analysis was carried out based on deconstructSigs using 30 COSMIC signatures. 27 The signatures of deamination, DSBR, smoking, MSI, UV, and POLE corresponded to signature numbers 1, 3, 4, 6, 7, and 10 in COSMIC, respectively.
To calculate the contribution ratio, APOBEC was combined with Signatures 2 and 13. Likewise, MMR was combined with Signatures 15, 20, and 26. In these signatures, a contribution ratio greater than 0.5 defined "predominant". The known fusion genes were checked by next-generation sequencing according to a previous report. 
| Expression analysis of immune-related genes
To establish a correspondence between somatic mutations and gene expression, microarray probes were selected according to the reference human genome (UCSC hg19). Raw signal intensity derived from the scanned image was filtered by Agilent Flag Values to ensure the reliability of the microarray data, and then log-transformed and normalized to the 75th percentile. To compare gene expression between samples, the z-score of target genes was calculated from fold change (tumor vs normal tissue in the same patient). In cases where dissection of the normal sample was problematic, the corresponding expression profile was excluded from the analysis. These data were prepared and outputted using GeneSpring GX software (Agilent Technologies) and a Subio Platform (Subio, Kagoshima, Japan). The immune-related gene set reflecting the tumor microenvironment was composed of MHC-, costimulation-, and inflammatory-related genes, as described in a previous report. 9 Hierarchical cluster analysis was undertaken using Ward's method in R (pheatmap in R package produced by Raivo Kolde) to divide data into 2 groups. Microarray analysis was carried out in accordance with MIAME guidelines. 
| Statistical analysis
For the comparisons of mutational signature, age, TMB, tumor cellularity, and VAF score, the assumption of normality and the equality of 2 variances were tested by the Jarque-Bera test and F test, respectively. Student's or Welch's t test was applied depending on the assumption of the F test concerning normal distribution. For comparison of samples under the assumption of non-normal distribution, a Mann-Whitney-Wilcoxon or Brunner-Munzel test (also known as "generalized Wilcoxon test") was carried out depending on the assumption of the F test. Microarray-derived gene expression data were normalized, and the significance of expression differences was calculated by Welch's t test. The significance for association between the mutations of the 2 groups was analyzed using Fisher's exact test.
To control the false discovery rate, the Benjamini-Hochberg procedure (q < 0.01) was carried out, and results were considered significant at P values < 0.01.
| RE SULTS
| Tissue distribution and TMB classification
We undertook WES in 4297 solid tumor samples derived from 4046 patients with cancer. Samples collected from our hospital comprised multiple tissues, among which colorectal, lung, stomach, head and neck, breast, and liver cancers accounted for 75% of the whole content ( Figure 1A and Table S1 ). To investigate the distribution of mutation frequency, we compared the TMB re- Additionally, the TMB range was classified into high, intermediate, low, and ultralow ( Figure 1B) . To reduce the probability of estimation errors due to low-frequency mutations, TMB-ultralow tumors (less than 1 mutation/Mb, ≈25th percentile) were excluded from mutational signature analysis. These samples showed a low detection rate of driver (pathogenic/likely pathogenic) mutations and known fusion genes in comparison with TMB-low tumors ( Figure S1 ).
| Tumor mutational burden and mutational signature
Mutational signature analysis was undertaken in TMB-high, -intermediate, and -low tumors (n = 3292). The profile of somatic mutation is visualized in Figure 2 . These signatures comprised more than 10 samples with a predominant contribution ratio higher than 0.5, based on deconstructSigs. 
| Microsatellite instability-predominant tumors
Consistent with previous reports, 1, 35, 36 the MSI signature was frequently observed in TMB-high tumors in our study (see Figure 2) . 
(A) ( B)
The MSI signature was predominant in 2.8% of all cases (122/4297), and 92 out of 122 samples were classified as TMB-high tumors, mainly derived from colorectum, stomach, and uterus ( Figure 4 ).
Moreover, MSI-predominant TMB-low tumors were observed in diverse tumor types ( Figure 4B ).
| Expression of immune-related genes and mutational signature
Although F I G U R E 5 Gene expression of immune-related genes in tumors with predominant mutational signatures. The deamination signature (known as Signature 1), which was found in most tumor types, was excluded from this analysis. The expression analysis was undertaken in gene sets reflecting the tumor microenvironment. 9 Heatmap representing gene clusters for different functions of immune-related genes is shown. The subgroup, mostly including upregulated genes, based on cluster analysis, was defined as C1; the subgroup including the remaining samples was designated as C2. In cases where dissection of the normal tissue was problematic due to tumor type, the sample was excluded from the analysis. Numbers of patients are shown in parentheses. With respect to tumor type, lung cancers were classified into adenocarcinoma (adenoca.), squamous cell carcinoma (SCC), and others. GIST, gastrointestinal stromal tumor; TMB, tumor mutational burden Tumor cellularity  Tumor type  TMB  CD3E  CD3G  CD4  CD8A  GNLY  GZMA  GZMB  GZMH   IFNG  TBX21  CD19  CD40  CD86  HLA-DMA  HLA-DMB  HLA-DOA  HLA-DOB  HLA-DPA1  HLA-DQA2  HLA-DRA  LTA  CXCR5  CXCL13  HLA-B  HLA-C  IFNA2  IL1A  IL1B  CXCL8  CXCR2   GZMK   CD274   T 
| D ISCUSS I ON
Mutational signatures were calculated from 96 nucleotide substitution patterns in somatic mutations. Signature analysis based on low-frequency mutations potentially leads to inaccurate estimation. 27 We thus removed TMB-ultralow tumors from our signature analysis. In the removed samples, known ( and C2 tumors.
The generation of several mutational signatures is associated with somatic mutations in specific genes. 1, [44] [45] [46] [47] In our analysis, the tendency of mutation accumulation was similar between C1 and C2 tumors with predominant signatures (see Figure S4A ). However, no relationship between somatic mutations and the expression of immune-related genes was found in these tumors. This finding suggested that the diversity of the immune context, including C1 and C2
tumors, was unsusceptible to recurrent somatic mutations.
In conclusion, the present study characterized the TMB and mutational signatures in 4046 Japanese patients with cancer (4297 samples) and found mutation frequencies and patterns similar to those reported by previous studies mainly involving Caucasian patients. Signature 16 was associated with alcohol consumption not only in liver cancer but also in tumors developing in sites that could be directly exposed to alcohol. Microsatellite instability-predominant tumors that are potential candidates for treatment with immune checkpoint inhibitors such as pembrolizumab were found in 2.8% of Japanese patients. The tumors with predominant signatures were classified into 2 subgroups depending on the expression of immune-related genes, which, in turn, reflected the tumor microenvironment. Tumor mutational burden and mutational signature analysis including the tumor microenvironment not only characterize mutation-driven tumors but could also help in prediction of response to immunotherapeutics.
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